SEC Form 4 · accession 0001553350-18-000031
HEAT BIOLOGICS, INC. · HTBX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ann A Rosar
Officer — VP of Finance
Period of report
Jan 8, 2018
Accepted (ET)
Jan 10, 2018 · 6:01 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001476963
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 8, 2018 | A | 45,000 | $0.00 | A | 108,236 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF2 | $0.40 | Jan 8, 2018 | A | 66,176 | A | Feb 1, 2018 | Jan 1, 2028 | Common Stock | 66,176 | 66,176 | D |
Explanation of responses
- F1The 45,000 shares of Heat Biologics, Inc. (the "Company") common stock, $0.0002 par value per share (the "Common Stock"), are represented by 45,000 restricted stock units ("RSUs") granted under the Company's stock incentive plan. Each RSU represents a contingent right to receive one share of Common Stock. The 45,000 RSUs vest as follows: (i) 11,250 vested on January 8, 2018; (ii) 11,250 will vest on January 8, 2019; (iii) 11,250 will vest on January 8, 2020; and (iv) 11,250 will vest on January 8, 2021, provided that the reporting person is not terminated for cause prior to such dates.
- F2These stock options vest monthly on a pro rata basis over a four year period commencing February 1, 2018.